

# Renal Insufficiency Global Market Report 2025: Key Trends, Market Size, and Growth Forecast

*The Business Research Company's Renal Insufficiency Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED KINGDOM, March 27, 2025

/EINPresswire.com/ -- Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.



What comprises the current market scenario and where is it expected to head in the future? The [renal insufficiency market size](#) has witnessed rapid growth in recent years, growing from \$10.87 billion in 2024 to \$12.14 billion in 2025 at a compound annual growth rate CAGR of 11.7%. This growth during the historic period can be largely attributed to increasing cases of high blood pressure and diabetes, higher prevalence of chronic kidney disease CKD, rising instance of obstructions in the urinary tract, aging population, and increasing awareness and education regarding kidney health.

What does the future hold for this market?

The renal insufficiency market size is showing signs of swift growth in the next few years. It is projected to grow to \$18.68 billion in 2029 at a compound annual growth rate CAGR of 11.4%. The growth in the forecast period can be attributed to increasing prevalence of acute kidney injuries AKI, expanding adoption of home-based treatment options, surge in healthcare expenditure, and robust investments in research and development. The major trends expected in the forecast period include advancements in medical technology, enhanced technology and treatment options, integration of personalized medicine, advancements in dialysis technology, and development of new and innovative medications.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=21271&type=smp>

What are the key factors propelling the growth of renal insufficiency market?

The increasing number of high blood pressure and diabetes cases is expected to significantly propel the growth of the renal insufficiency market moving forward. Factors such as poor diet, lack of physical activity, obesity, genetic predisposition, and an aging population contribute to both blood pressure and diabetes. These conditions harm kidney blood vessels by causing scarring and reduced filtration, leading to thickened and overworked kidney vessels due to high blood sugar, accelerating kidney damage and resultant renal insufficiency.

For instance, in May 2024, according to the National Health Service, a UK-based government agency, in December 2023, the number of high blood pressure diagnoses in the South East increased by 71,120 patients, marking a 5.4% rise compared to December 2022. Furthermore, in April 2023, according to the British Diabetic Association, a UK-based charity organization, 4.3 million people are living with a diabetes diagnosis in the UK. Therefore, the increasing number of high blood pressure and diabetes cases is fueling the growth of the renal insufficiency market.

What are the key industry players and recent advancements?

Major companies operating in the renal insufficiency market include Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation, Sorin Group.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/renal-insufficiency-global-market-report>

What are the dominant trends in the sector?

Major firms in the renal insufficiency market are developing glucagon-like peptide-1 receptor agonists GLP-1 RAs to mitigate renal and cardiovascular complications in patients with diabetes and chronic kidney disease CKD. GLP-1 RAs improve glucose control, lessen inflammation, and lowers oxidative stress in the kidneys, thus decelerating the progression of renal insufficiency. For instance, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, received Food and Drug Administration FDA approval for its Ozempic semaglutide to reduce the risk of kidney disease worsening, kidney failure, and cardiovascular death among adults with type 2 diabetes and chronic kidney disease CKD. This approval underscores the growing emphasis on glucagon-like peptide-1 receptor agonists GLP-1 RAs as a dual strategy for managing both diabetes and renal insufficiency, addressing critical unmet needs in patients with progressive CKD.

How is the [renal insufficiency market segmented](#)?

The renal insufficiency market covered in this report is primarily divided into –

- 1 By Treatment Type: Medications, Dialysis, Kidney Transplantation, Other Treatment Types
- 2 By Disease Stage: Chronic Kidney Disease CKD Stages, End-Stage Renal Disease ESRD

3 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies  
4 By End-User: Dialysis Centers, Hospital And Clinics, Research And Academic Institutes

Additional subsegments are:

1 By Medications: Angiotensin-Converting Enzyme ACE Inhibitors, Angiotensin II Receptor Blockers ARBs, Diuretics, Erythropoiesis-Stimulating Agents ESAs, Phosphate Binders, Sodium Bicarbonate  
2 By Dialysis: Hemodialysis, Peritoneal Dialysis, Home Dialysis, Continuous Renal Replacement Therapy CRRT  
3 By Kidney Transplantation: Living Donor Kidney Transplant, Deceased Donor Kidney Transplant, Kidney Transplant Immunosuppressive Therapy  
4 By Other Treatment Types: Lifestyle And Dietary Modifications, Stem Cell Therapy, Gene Therapy

What are the regional insights?

In 2024, North America secured the top position in the renal insufficiency market. The report also provides insights on other regions, namely, Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse For More Similar Reports-

End Stage Renal Disease (ESRD) Drug Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report>

Hepatorenal Syndrome Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report>

Renal Denervation Devices Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/renal-denervation-devices-global-market-report>

About [The Business Research Company](#)

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company offers comprehensive, data-rich research and insights. Backed by 1,500,000 datasets, in-depth secondary research, and unique insights from industry leaders, you can stay ahead in the game with our reports.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708  
Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_f10rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/797620925>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.